ArticleFrontiers in public health2026
Assessment of health-related quality of life of patients with gout and hyperuricemia in the Tianjin area according to the SF-6Dv2 scale.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The number of patients with hyperuricemia and gout is constantly rising and the conditions are seriously affecting their quality of life. Thus, it is of great importance to identify a assessment scale to assess the quality of life suitable for the Chinese population. The aim of this study was to evaluate the health-related quality of life (HRQoL) of patients with hyperuricemia and gout in Tianjin, using the Short Form of 6-Dimensions Health 2nd version (SF-6Dv2) scale, and to explore its influencing factors. Methods: A total of 171 patients who visited the hyperuricemia gout clinic in a Class III and Grade A hospital were collected from September 2022 to May 2024. The SF-6Dv2 scale was completed by face-to-face interview and its utility value was measured. Sex- and age-matched individuals from the community and a healthy population on physical examination from the same hospital served as the control group. This study compared the HRQoL of respondents through the SF-6Dv2 score and explored its influencing factors. Results: A total of 171 patients (mean [SD] age: 45.34 [16.60] years) and 171 respondents (mean [SD] age: 41.24[16.60] years) from the control population were included. The mean utility value of the disease group was 0.671 (0.270), which was significantly lower than that of the control group (0.803 [0.155], Conclusion: This study found that the utility value of the SF-6Dv2 scale for patients with hyperuricemia was lower than that of the control group. Furthermore, the level of triglycerides, the preference for seafood, the severity of hyperuricemia and gout, and marital status of the patients were correlated with the HRQoL of the patients with hyperuricemia and gout. This findings of this study have important practical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.